228467 Finsbury WWH pp37-pp44 18 06 2013 10:41 Page 37 Directors Remuneration Report 37 Directors Remuneration Report The Board has prepared this report in accordance with the incentive schemes or other benefits.
The policy is for the requirements of Section 420 to 422 of the Companies Act 2006.
Chairman of the Board, Chairman of the Audit Committee and An ordinary resolution for the approval of this report will be put the Senior Independent Director to be paid higher fees than the to the members at the forthcoming Annual General Meeting.
other Directors to reflect their additional responsibilities.
The law requires the Companys auditors to audit certain of the DIRECTORS SERVICE CONTRACTS disclosures provided.
Where disclosures have been audited, It is the Boards policy that none of the Directors has a service they are indicated as such.
The Auditors opinion is included in contract.
The terms of their appointment provide that Directors their report on pages 39 and 40. shall retire and be subject to election at the first Annual General Meeting after their appointment and re-election annually MANAGEMENT ENGAGEMENT AND thereafter.
The terms also provide that a Director may resign by REMUNERATION COMMITTEE notice in writing to the Board at any time and may be removed The Company has seven non-executive Directors, six of whom without notice and that compensation will not be due on are considered by the Board to be independent.
Up until 31 March 2013 the Companys policy was Board, with the exception of Mr Isaly, fulfills the function of the for the Directors to be remunerated in the form of fees payable Management Engagement and Remuneration Committee.
The quarterly in arrears, to the Director personally or to a specified Board may utilise the services of the Company Secretary or third party.
With effect from 1 April 2013 Directors will be paid external advisers to provide advice when the Directors consider monthly in arrears in accordance with new legislation by HMRC.
the level of Directors fees.
The Directors fees are reviewed annually by the Management YOUR COMPANYS PERFORMANCE Engagement and Remuneration Committee and such review The Regulations require a line graph be included in the will not necessarily result in a change to the rates paid.
During Directors Remuneration Report comparing, for a period of five the year, the Management Engagement and Remuneration years, on a cumulative basis, the total share price return Committee carried out a review of the level of Directors fees in assuming all dividends are reinvested to shareholders and the relation both to fees paid to the boards of other investment total shareholder return on a notional investment made up of trust companies and also to the Boards corporate governance shares of the same kind and number as those by reference to obligations.
The Board decided, on the advice of the the Companys stated benchmark.
With effect from 1 October Management Engagement and Remuneration Committee, that 2010, the performance of the Company has been measured the fees paid to the Directors should be increased with effect against the MSCI World Health Care Index on a net total return, from 1 April 2013.
The revised fee levels are set out on page 38. sterling adjusted basis.
Prior to this date, performance was measured against the Datastream World Pharmaceutical & POLICY ON DIRECTORS FEES Biotechnology Index total return, sterling adjusted.
Therefore, The Boards policy is that the remuneration of Directors should the benchmark return for the year ended 31 March 2013 reflect the experience of the Board as a whole, be fair and represented in the graph overleaf consists of a blended figure comparable to that of other investment trusts that are similar in containing both indices.
size, have a similar capital structure and have a similar investment objective.
It is intended that this policy will continue for the year ending 31 March 2014 and subsequent years.
The fees for the Directors are determined within the limits set out in the Companys Articles of Association, the maximum aggregate amount currently being 200,000.
Directors are not eligible for bonuses, pension benefits, share options, long-term Worldwide Healthcare Trust PLC Annual Report 2013 228467 Finsbury WWH pp37-pp44 18 06 2013 10:41 Page 38 38 Directors Remuneration Report Directors Remuneration Report continued DIRECTORS EMOLUMENTS FOR THE YEAR AUDITED The Directors who served in the year received the following emoluments in the form of fees: Level of fees with effect from 1 April 2013 Fees Fees unaudited 2013 2012 000 000 000 Martin Smith Chairman of the Board 39.2 38.0 36.5 Sarah Bates appointed 22 May 2013 24.8 Jo Dixon Chairman of the Audit Committee 27.9 27.0 26.0 Paul Gaunt retired on 7 July 2011 8.0 Professor Duncan Geddes retired on 17 July 2012 7.0 23.5 Dr David Holbrook 24.8 24.0 23.0 Samuel D. Isaly 24.8 24.0 23.0 Doug McCutcheon appointed on 7 November 2012 24.8 10.0 Anthony Townsend Senior Independent Director 25.3 24.0 23.0 154.0 163.0 SHAREHOLDER TOTAL RETURN FOR THE FIVE YEARS TO 31 MARCH 2013 260 240 220 200 180 160 140 120 100 80 60 Mar Mar Mar Mar Mar Mar 08 09 10 11 12 13 Benchmark index Worldwide Healthcare Share price Rebased to 100 as at 31 March 2008 Source: Morningstar, Thomson Reuters and Bloomberg APPROVAL The Directors Remuneration Report on pages 37 and 38 was approved by the Board of Directors on 6 June 2013 and signed on its behalf by: Sir Martin Smith Chairman Worldwide Healthcare Trust PLC Annual Report 2013
